Log In
BCIQ
Print this Print this
 

irdabisant (CEP-26401)

  Manage Alerts
Collapse Summary General Information
Company Teva Pharmaceutical Industries Ltd.
DescriptionH3 antagonist
Molecular Target Histamine H3 receptor (HRH3)
Mechanism of ActionHistamine H3 receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationCognitive dysfunction
Indication DetailsTreat cognition in Alzheimer's disease and schizophrenia
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today